Keytruda (pembrolizumab) Disease area(s): Oncology Manufacturer(s): Merck 2024 Sales (USD): $29.48 billion Why it sold so well: Mercks flagship cancer immunotherapy Keytruda achieved expected, remarkable success in 2024, with global sales reaching $29.48 billion an 18% increase from the previous year and accounting for 46% of the companys total revenue
How BPC-157 (Oral) Works Oral BPC-157 acts primarily through local gastrointestinal mechanisms and, to a debated extent, through systemic absorption from the gut
Attentive examination and follow-up of patients, especially those at high risk, are required to improve early detection of rare MMs, ensuring that malignancies are not missed
486 The axon damages caused by SARM1 or NMNAT2 can be restored by increasing NAD + synthesis, like over-expressing the NMNAT2 enzyme
Crafted with meticulous attention to detail, this cutting-edge liquid Carnitine ensures maximum purity and bioavailability to help it quickly and easily be absorbed
One Phase 2 trial of lixisenatide in Parkinsons did meet its primary motor endpoint, the biology of GLP-1 in the brain is real, and questions remain about earlier intervention, specific subpopulations, and whether vascular or metabolic contributions to neurodegeneration might still respond